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Abstract
Background: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two
large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone
compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the approval of
lenalidomide for RMM patients and lenalidomide/dexamethasone has since become a widely accepted second-line
treatment. Furthermore, in RMM patients consolidation with high-dose chemotherapy plus autologous stem cell
transplantation has been shown to significantly increase progression free survival (PFS) as compared to
cyclophosphamide in a phase III trial. The randomized prospective ReLApsE trial is designed to evaluate PFS after
lenalidomide/dexamethasone induction, high-dose chemotherapy consolidation plus autologous stem cell
transplantation and lenalidomide maintenance compared with the well-established lenalidomide/dexamethasone
regimen in RMM patients.
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Methods/Design: ReLApsE is a randomized, open, multicenter phase III trial in a planned study population of 282
RMM patients. All patients receive three lenalidomide/dexamethasone cycles and - in absence of available stem
cells from earlier harvesting - undergo peripheral blood stem cell mobilization and harvesting. Subsequently,
patients in arm A continue on consecutive lenalidomide/dexamethasone cycles, patients in arm B undergo high
dose chemotherapy plus autologous stem cell transplantation followed by lenalidomide maintenance until
discontinuation criteria are met. Therapeutic response is evaluated after the 3rd (arm A + B) and the 5th
lenalidomide/dexamethasone cycle (arm A) or 2 months after autologous stem cell transplantation (arm B) and
every 3 months thereafter (arm A + B). After finishing the study treatment, patients are followed up for survival and
subsequent myeloma therapies. The expected trial duration is 6.25 years from first patient in to last patient out. The
primary endpoint is PFS, secondary endpoints include overall survival (OS), RR, time to best response and the
influence of early versus late salvage high dose chemotherapy plus autologous stem cell transplantation on OS.
Discussion: This phase III trial is designed to evaluate whether high dose chemotherapy plus autologous stem cell
transplantation and lenalidomide maintenance after lenalidomide/dexamethasone induction improves PFS
compared with the well-established continued lenalidomide/dexamethasone regimen in RMM patients. Trial
registration: ISRCTN16345835 (date of registration 2010-08-24).
Keywords: Multiple myeloma, Relapse, Second-line treatment, Lenalidomide, Autologous stem cell transplantation,
High-dose chemotherapy
Background
With an incidence rate of 5-6/100.000, multiple myeloma
(MM) accounts for 13 % of hematologic cancers and 1 % of
all neoplastic diseases in Western countries [1]. In first-line
treatment of MM, high-dose chemotherapy (HDCT) with
subsequent autologous stem-cell transplantation (ASCT)
has become the standard of care in eligible patients [1–3].
In recent years patient outcomes have been further im-
proved by the introduction of novel agents, namely immu-
nomodulatory drugs (IMiDs) and proteasome inhibitors
(PIs) into first-line therapy. Nevertheless, MM remains
largely incurable and almost all patients eventually relapse.
Therapeutic options in the setting of relapsed MM (RMM)
include salvage HDCT/ASCT, novel agents (IMiDs, PIs,
agents under clinical investigation), chemotherapy, cortico-
steroids, and allogeneic stem cell transplantation [4]. In the
absence of an established standard of care the selection of a
suitable treatment regimen for RMM patients is usually
based on disease- and patient-specific factors such as regi-
mens employed in and response to prior lines of therapy.
Again, the introduction of IMIDs and proteasome inhibi-
tors into the treatment of RMM has led to a major increase
in survival rates of this patient population [4–11].
Lenalidomide is an orally administered IMiD and a
derivative of the structurally related thalidomide [12].
The mechanism of action of lenalidomide is multifaceted
[13, 14] including apoptosis induction, alteration of the
interaction of myeloma cells with bone marrow stroma
[15], antiangiogenesis [16, 17], and immunomodulation
[18, 19]. More recently, anti-myeloma activity of lena-
lidomide has been shown to depend on interaction with
cereblon, a protein involved in the teratogenicity of thal-
idomide [20–22]. Two pivotal phase III trials (MM-009
and MM-010) have demonstrated highly significant
improvement of response rates with lenalidomide/
dexamethasone compared with placebo/dexamethasone
in a total of 704 RMM patients and subsequently led to
regulatory approval of lenalidomide in the USA and the
EU. All patients in these pivotal trials received 40 mg
dexamethasone on days 1–4, 9–12 and 17–20 and either
25 mg lenalidomide or placebo on days 1–21 of 28-day cy-
cles. After completion of the 4th cycle, dexamethasone
was limited to days 1–4 [8, 9]. Pooled analysis of both
registration studies revealed superior overall response rate
(ORR; 60.6 % vs. 21.9 %), time to progression (TTP; 13.4
vs. 4.6 months) and median OS (38.0 vs. 31.6 months) of
the lenalidomide-containing regimen, but also significantly
more adverse events (AEs), especially grade 3–4 neutro-
penia (35.4 % vs. 3.4 %) and thromboembolic events
(15.9 % vs. 5.4 %) [23]. Dexamethasone dosing was subject
of investigation in a phase III trial in NDMM patients. In
combination with lenalidomide, high-dose dexamethasone
(480 mg/cycle; 40 mg on days 1–4, 9–12 and 17–20) led
to significantly increased ORR (79 % vs. 68 %), but low
dose-dexamethasone (160 mg/cycle; 40 mg on days 1, 8,
15, 22) showed significantly increased OS after 1 and
2 years (96 % vs. 87 % and 87 % vs. 75 %, respectively).
This was related to a significantly lower incidence of AEs
including infectious and thromboembolic events and
deaths in the low-dose dexamethasone arm [24]. A sub-
group analysis of RMM patients from MM-009 and MM-
010 with dexamethasone dose reduction confirmed these
results [25]. Furthermore, lenalidomide maintenance
treatment has been evaluated in four phase III trials in
NDMM patients [26–29]. While PFS after lenalidomide
maintenance was markedly prolonged in all four trials, OS
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was significantly superior in only one trial [30]. Despite
the finding of an increased incidence of second primary
malignancies in the maintenance arm, the odds for lower
mortality are in favor of lenalidomide maintenance treat-
ment [31].
Available data on HDCT/ASCT in RMM patients
largely comes from retrospective, non-randomized,
single-center or registry-based studies [32–45] and few
prospective trials of early (i.e. first-line) vs. delayed (i.e.
second-line) HDCT/ASCT [46, 47]. These studies
suggest that salvage HDCT/ASCT is feasible in RMM
patients considered eligible based on sufficient general
condition and absence of prohibitive comorbidities.
However, reported outcomes vary due to small and/or
heterogeneous patient populations and differing salvage
regimens. A recently published review of 19 retrospect-
ive studies of salvage HDCT/ASCT in patients treated
with first-line HDCT/ASCT reported median ORR of
64.3 % (range 27.3 to 97.4 %), median PFS of 12.3 months
(range 6 to 36 months), median OS of 32.4 months
(range 8 to 79.1 months) and median transplantation as-
sociated mortality (TRM) of 4.1 % (range 0 to 22 %).
TTP after first-line HDCT/ASCT of ≥ 19.8 months
(range 6 to 36 months) was identified as the major pre-
dictive factor for a beneficial outcome after salvage
HDCT/ASCT. Furthermore, the quality of response after
first-line HDCT/ASCT and the number of prior lines of
therapy were suggested as predictive factors [48]. A
similar, retrospective study from our center involving
200 patients treated between 1995 and 2010 with salvage
HDCT/ASCT at relapse after first-line HDCT/ASCT
yielded comparable results with median ORR of 80.4 %,
median PFS of 15.4 months, median OS of 42.3 months
and TRM of 3 %. An overall survival advantage for pa-
tients treated with bortezomib or lenalidomide during
reinduction suggested that salvage HDCT/ASCT and
novel agents are complementary treatment approaches.
Moreover, a favorable cytogenetic status (i.e. absence
of +1q21, del(17p13) and t(4;14)) was associated with sig-
nificantly prolonged PFS (25.6 vs. 13.2 months) [41]. Re-
cently, results from the first prospective, randomized trial
on salvage HDCT/ASCT in patients with a previous
HDCT/ASCT have been published [49]. At first relapse at
least 18 months (later reduced to 12 months) after
previous HDCT/ASCT, 293 patients were treated with
bortezomib/doxorubicin/dexamethasone (PAD) reinduc-
tion therapy and underwent stem cell mobilization and
harvesting if applicable. Subsequently, 174 eligible patients
were randomized on a 1:1 basis to receive either HDCT
(melphalan 200 mg/m2) and ASCT or cyclophosphamide
(400 mg/m2 per week for 12 weeks) consolidation therapy.
ORR in the HDCT/ASCT arm was 83 % compared with
75 % in the cyclophosphamide arm with significantly more
very good partial remissions or better after HDCT/ASCT
(60 % vs. 47 %). The primary endpoint of median TTP was
significantly prolonged (19 vs. 11 months). OS did not dif-
fer significantly with median OS not having been reached
at the cut off date for the final analysis and 3-year OS of
80.3 % vs. 62.9 %. TRM was 1 % in the HDCT/ASCT arm.
A subgroup with an unfavorable cytogenetic status (i.e.
t(4;14), t(14;16) and/or del(17p13)) did not benefit from
HDCT/ASCT (hazard ratio (HR) 2.41). However, the low
proportion of patients with available cytogenetic data
(51 % of patients undergoing randomization) and the low
number of patients with an unfavorable cytogenetic status
(n = 13; 15 %) limit the interpretation of this finding.
Existing evidence suggests both feasibility and benefit
of salvage HDCT/ASCT in eligible RMM patients.
Moreover, novel agent based regimens and HDCT/
ASCT seem to be complementary salvage treatment ap-
proaches. The ReLApsE trial is designed to analyze the
benefit of salvage HDCT/ASCT incorporated into the
widely used and novel agent based salvage treatment
lenalidomide/dexamethasone (Rd) in a prospective, ran-
domized setting.
Methods/Design
Design
ReLApsE is a randomized, controlled, open-label, multi-
center phase III trial in a planned study population of 282
RMM patients in their 1st to 3rd relapse. Patients are ran-
domized 1:1 to receive either Rd reinduction, HDCT/
ASCT and lenalidomide maintenance or continued Rd.
Patients are stratified according to study site and HDCT/
ASCT during first-line therapy (yes vs. no). The protocol
published here is based on the full protocol version 4.0 as
of 2014-04-15.
Trial objectives
Primary objective
PFS is defined as time from randomization to progres-
sive disease (PD) or death, irrespective of the cause of
death, and is evaluated as primary objective. Patients
that are event-free at the time of analysis are censored at
the date of the last response evaluation.
Secondary objectives
Secondary objectives are: OS; response rates to Rd,
HDCT/ASCT and lenalidomide maintenance; time to best
response; impact of complete response (CR) and very
good partial response (VGPR) prior to HDCT/ASCT and
prior to lenalidomide maintenance on PFS and OS; impact
of early salvage HDCT/ASCT with subsequent lenalido-
mide maintenance versus late salvage HDCT/ASCT (per-
formed as a post-study treatment) on OS; feasibility of
stem cell mobilization and apheresis; safety and toxicity
(type, frequency, CTC grading, causality of AEs); time to
initiation of next anti-myeloma treatment.
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Setting
ReLApsE is an investigator initiated trial designed and car-
ried out by the German-Speaking Myeloma Multicenter
Group (GMMG). The trial setting is multicentric with 16
participating study sites located in Germany: Helios
Hospital Berlin-Buch; Charité Campus Benjamin Franklin,
Berlin; Community Hospital Bielefeld; University Hospital
Bonn; Klinikum Chemnitz GmbH; University Hospital
Düsseldorf; University Hospital Essen; Evangelisches
Krankenhaus Essen-Werden gGmbH; Goethe University,
Frankfurt; Katholisches Krankenhaus Hagen gGmbH;
Asklepios Klinik Altona, Hamburg; Heidelberg University
Hospital (trial sponsor); University Hospital Cologne;
University Hospital Mannheim; Maria-Hilf-Krankenhaus
Mönchengladbach; University Hospital Tübingen.
Estimated timeline
Recruitment of study patients was initiated during the
4th quarter of 2010 (first patient in; FPI) and is planned
to be completed during the 4th quarter of 2015 (last pa-
tient in; LPI). The trial is planned to be finished during
the 1st quarter of 2017 (last patient out; LPO), 1.25 years
after LPI. An interim analysis is planned after 96 PFS
relevant events. The final report is scheduled for the 1st
quarter of 2018. Patients with continued benefit from
treatment at the end of the trial will be allowed to con-
tinue treatment. For patients in arm B receiving main-
tenance lenalidomide at the end of the trial, Celgene
provides lenalidomide until disease progression at no
cost.
Ethical aspects, informed consent, and safety
All study procedures are in accordance with Inter-
national Conference on Harmonization of good clinical
practice (ICH-GCP) guidelines, the declaration of
Helsinki, and German laws, regulations and organiza-
tions. Documented approval from the ethics commit-
tees/institutional review boards (IRB) of the Medical
Faculty of the Heidelberg University (main IRB) and all
participating study sites has been obtained prior to study
start and a data safety monitoring board (DSMB) has
been installed to monitor the trial.
Written informed consent from each patient is ob-
tained before any study-specific procedures are per-
formed. Study participation and date of informed
consent are documented in each patient’s files.
AEs are recorded in the patient’s case report form and
relatedness to the study medication, intensity (according
to CTCAE v4.03) and severity are classified. Serious AEs
(SAEs) are recorded on an additional SAE form and are
reported to the responsible safety officer within 24 h of
detection. Suspected unexpected serious adverse reac-
tions (SUSARs) are reported to the responsible ethics
committee, the federal authorities and all investigators.
Due to the teratogenicity of lenalidomide a pregnancy
prevention program was implemented.
Selection of trial patients
Inclusion and exclusion criteria are listed in Table 1.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Understanding of the nature and consequences of the trial and
voluntary signature of the informed consent document
• Age≥ 18 and≤ 75 years at the time of consent and randomization
• Availability of stem cells from earlier harvesting if age ≥ 71 years
• 1st to 3rd relapse of symptomatic MM (according to IMWG criteria [51])
• Salmon and Durie stage [58] II or III
• Duration of response≥ 12 months in case of first-line HDCT/ASCT
• WHO performance status (WHO PS) ≤ 2
• Laboratory findings within the following ranges
○ Absolute neutrophil count≥ 1/nl
○ Platelet count≥ 75/nl (depending on bone marrow infiltration with
myeloma cells, platelet count≥ 30/nl may be acceptable)
○ Creatinine clearance≥ 30 ml/min
○ Total bilirubin≤ 2 x the upper limit of normal (ULN; except for
elevations caused by MM)
○ Alanine aminotransferase (ALT)≤ 3 x ULN (except for elevations
caused by MM)
• Absence of malignant diseases other than MM for ≥ 5 years (except
basal-cell carcinoma and carcinoma in situ of the skin, the cervix and
the breast)
• Ability to apply thrombosis prophylaxis
• Consent to all protocol requirements, especially those regarding the
trial visit schedule and the pregnancy prevention program
Exclusion criteria
• Pregnant or breastfeeding female
• Previous treatment with lenalidomide, if:
○ Refractory (i.e. stable disease (SD) or progressive disease (PD) on
treatment or ≤ 60 days after the end of treatment)
○ PD≤ 6 months after the end of treatment if patient had responded
(i.e. ≥ MR)
• Previous salvage HDCT/ASCT
• Known hypersensitivity to thalidomide, lenalidomide or components
of lenalidomide
• Erythema nodosum as an exfoliative rash while on thalidomide
• Exposure to any other experimental substance within 28 days prior to
enrollment
• Non-secretory MM (with normal free light chain ratio) that cannot be
monitored by radiographic (e.g. MRI) examination
• Systemic amyloidosis with organ involvement (with the exception of
AL-amyloidosis of the skin and/or bone marrow)
• Plasma cell leukemia
• Previous allogeneic stem cell transplantation
• Active, uncontrolled infectious disease
• Known positivity for HIV, hepatitis B or C
• Congestive heart failure (NYHA≥ 3)
• Severe pulmonary, neurologic or psychiatric disease
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Trial procedures
An overview of the trial procedures and a checklist ac-
cording to “Standard Protocol Items: Recommendations
for Interventional Trials” (SPIRIT) guidelines are pro-
vided as Additional files 1 and 2.
Screening
The following diagnostic investigations are performed at
screening to determine patient eligibility for study
participation and to assess disease status before study
treatment: patient history and physical examination
(including body weight, height, WHO performance score
(PS), and concomitant diseases), laboratory investiga-
tions (complete blood count including absolute neutro-
phil count (ANC), electrolytes, renal parameters, hepatic
parameters, thyroid stimulating hormone, C reactive
protein, lactate dehydrogenase, albumin, total protein,
pregnancy test if applicable, β-2 microglobulin, immuno-
globulins, monoclonal protein and free light chains in
serum, monoclonal protein in urine, immunofixation in
serum and urine), bone marrow aspiration (cytology,
interphase fluorescence in situ hybridization (iFISH) in
CD138-purified plasma cells as described previously
[50]) radiographic imaging of the skeleton (low dose,
whole body computed tomography (CT) or conventional
X-ray imaging; appropriate imaging for disease quantifi-
cation in case of non-secretory myeloma), electrocardio-
gram (ECG) and echocardiogram (exercise ECG if
clinically indicated).
Study visits
Study visits are scheduled at the respective study site after
the initial 3 Rd cycles, after Rd cycle 5 (arm A) or 2 months
after HDCT/ASCT (arm B), every three months thereafter
and at the end of study participation. Diagnostic investiga-
tions performed at these visits for assessment of efficacy
and safety, as well as patient eligibility to continue study
treatment include: patient history and physical examination
(including AEs, WHO PS, signs of thrombosis, assessment
of soft tissue plasmacytomas), laboratory investigations
(listed in Screening), bone marrow aspiration (only if CR or
PD are suspected), radiographic imaging of the skeleton (if
clinically indicated or at least once a year; more frequently
for response assessment in non-secretory MM), and ECG
and echocardiography (after the initial 3 Rd cycles, before
HDCT and if clinically indicated). Additionally, complete
blood counts including ANC are determined weekly during
Rd cycles 1 and 2 and every 2 to 4 weeks thereafter for
safety reasons. During HDCT/ASCT safety investigations
are performed according to study site standards.
Trial treatment
An overview of the treatment schedule is provided in
Fig. 1. Following randomization, all patients receive
reinduction treatment consisting of 3 Rd cycles of
28 days each (oral lenalidomide 25 mg on days 1–21,
oral dexamethasone 40 mg on days 1, 8, 15, 22). Subse-
quently, all patients that do not have available stem cells
from earlier harvesting (≥2*106 CD34+ cells*kg bw−1)
undergo peripheral blood stem cell mobilization and
harvesting. Stem cell mobilization consists of cyclophos-
phamide (2 g*m−2 i.v. daily on days 1 and 2) and G-CSF
(filgrastim 10 μg*kg−1*d−1 or lenograstim 300 μg*m−2*d−1
s.c. from day 5 until the end of apheresis); if unsuccessful,
rescue mobilization with plerixafor is recommended.
Determination of CD34+ cells in peripheral blood and leu-
kapheresis are performed according to study site standard.
Patients in arm A then continue on consecutive Rd cy-
cles (same dosages and intervals as reinduction treat-
ment) until termination criteria are met.
Patients in arm B are examined for HDCT/ASCT
eligibility (available stem cells; WHO PS ≤ 2; absence of
severe pulmonary, neurologic, or psychiatric disease;
transaminases and bilirubin ≤ 2,5 ULN; NYHA ≤ 2) and -
if eligible - undergo HDCT (melphalan 100 mg*m−2 i.v.
daily on days -3 and -2) and autologous stem cell trans-
plantation (≥ 2*106 CD34+ cells*kg bw−1 i.v. on day 0)
no later than 5 weeks after the end of reinduction treat-
ment or stem cell harvesting. In the absence of ANC <
1/nl, platelets < 30/nl, active infections and PD, mainten-
ance treatment with oral lenalidomide (10 mg daily) is
initiated no later than 8 weeks after ASCT. Maintenance
treatment is continued until termination criteria are
met.
In the case of toxicities (e.g. grade 3/4 neutropenia,
thrombocytopenia, non-hematologic toxicities) attributed
to the study medication, doses of lenalidomide and/or
dexamethasone are reduced according to predefined algo-
rithms based on the prescribing information. All medica-
tion is adapted to renal function according to the
prescribing information if necessary. Melphalan is reduced
to a single dose of 100 mg*m−2 (day -3) if creatinine clear-
ance is ≤ 40 ml*min−1.
Supportive treatment
During cycle 1 of the reinduction treatment, all patients re-
ceive antibiotic prophylaxis with ciprofloxacin (500 mg
twice daily). Antibiotic prophylaxis after cycle 1 is optional
and based on clinical judgment. During reinduction treat-
ment, all patients with platelets ≥ 50/nl receive thrombosis
prophylaxis with low molecular weight heparin (LMWH;
enoxaparin 40 mg s.c. daily). In arm A, thrombosis prophy-
laxis is switched to oral acetylsalicylic acid (100 mg daily)
after Rd cycle 3 if no risk factors for thrombotic events are
present; otherwise prophylaxis with LMWH is continued
throughout the study treatment. During maintenance treat-
ment in arm B thrombosis prophylaxis is not mandatory;
however, it may be instituted based on clinical judgment.
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Supportive treatment during stem cell mobilization/
harvesting and HDCT/ASCT is performed according to
study site standards.
Moreover, all patients are recommended to receive
bisphosphonates (zoledronic acid 4 mg every 4 weeks
i.v.). If VGPR is reached, duration of bisphosphonates
should be limited to a total of 2 years. Due to the risk of
bisphosphonate related osteonecrosis of the jaw, regular
dental prophylaxis and temporary discontinuation of
bisphosphonates as well as antibiotic prophylaxis in the
context of invasive dental procedures are recommended.
Concomitant medication and treatment
Antibiotic prophylaxis, thrombosis prophylaxis and bis-
phosphonate treatment are administered as described
above. Furthermore, red blood cell and platelet transfu-
sions, G-CSF administration, immunoglobulin substitution,
treatment of myeloma- or treatment-associated complica-
tions, radiotherapy for the treatment of myeloma-induced
pain, and glucocorticoids up to 10 mg of prednisone
for the treatment of concomitant diseases are permitted.
Substances with antineoplastic activity other than those
administered according to the trial protocol are not
allowed.
Follow up
All patients are followed up after the end of study treat-
ment on a regular basis, irrespective of the reason for
discontinuation. During follow up, data on survival, tox-
icities, efficacy and subsequent myeloma-specific treat-
ment including salvage HDCT/ASCT are collected.
Response assessment
Disease response is determined based on International
Myeloma Working Group (IMWG) criteria [51]. Min-
imal response (MR) as defined in the European Group
for Bone and Marrow Transplantation (EBMT) criteria
[52] is assessed additionally. IMWG defined stringent
CR is not assessed and IMWG defined relapse from CR
is not considered for PFS calculation. Instead, the
IMWG definition of PD is also used for PFS calculation
of patients with CR.
Fig. 1 ReLApsE trial overview. Rd: 28 day cycle of lenalidomide (25 mg p.o. daily on days 1-21) and low-dose dexamethoasone (40 mg p.o. daily
on days 1, 8, 15, 22); cyclophosphamide: 2 g*m−2 i.v. daily on days 1 and 2; G-CSF: Filgrastim 10 μg*kg−1*d−1 or lenograstim 300 μg*m−2*d−1 s.c.
daily from day 5 until the end of apheresis; HDCT: High dose chemotherapy (melphalan 100 mg*m−2 i.v. daily on days -3 and -2); ASCT: Autologous
stem cell transplantation (≥ 2*106 CD34+ cells*kg bw−1 on day 0); R-maintenance: Lenalidomide maintenance (10 mg p.o. daily)
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Discontinuation criteria
Discontinuation of trial participation of individual patients
In the case of any of the following events, trial participa-
tion of the patient in question is discontinued: patient
wishes to discontinue study participation; continued
study participation is disadvantageous for the patient ac-
cording to the investigator; emergence of an exclusion
criterion that precludes further participation in the trial
according to the principal investigator; emergence of a
(serious) AE that precludes further participation in the
trial; pregnancy (for female patients); incorrect data due to
protocol violations by the patient (e.g. non-compliance);
confirmed PD or PD causing end organ damage (CRAB
criteria [53]), with the exception of asymptomatic PD after
stem cell apheresis; trial completion according to the
protocol.
Closure of individual trial sites
The principal investigator may prematurely close indi-
vidual trial sites in the case of inadequate recruiting or
data quality provided by the trial site in question.
Premature termination of the trial
The trial may be terminated prematurely by the princi-
pal investigator or the DSMB in the case of previously
unknown risks or inadequate recruiting.
Statistical analysis
Power calculation
The calculated number of total trial patients required to
prove clinically relevant inferiority of PFS in arm A vs.
arm B at a power of 80 % is 282. This power calculation
is based on the formula of Schoenfeld [54] and the fol-
lowing assumptions: median PFS in arm A of 11 months
(see prescribing information of lenalidomide); median
PFS in arm B of 16.5 months (HR 0.67); Type 1 error of
α = 0.05 with an α-spending according to O’Brien and
Fleming [55] of 0.0052 for the planned interim analysis
and 0.048 for the final analysis; power (1-β) of 0.8; 1:1
randomization; constant HR; interim analysis (O’Brien-
Fleming Boundaries [55]); 15 % loss to follow up/non-
compliance.
Study populations for analyses
Efficacy analyses are performed on an intent-to-treat
(ITT) basis. The ITT population consists of all random-
ized patients. Patients with severe violation of inclusion/
exclusion criteria are excluded. Patients are analyzed ac-
cording to their randomization result. Safety analyses
(toxicity, tolerability, medication) are performed on all
patients that have received at least one administration of
treatment according to the protocol. Patients are ana-
lyzed according to the received treatment.
Statistical methods
The primary objective (PFS) is analyzed on a confirmatory
basis at a two-sided significance level of α = 0.048, which
represents a significance level of α = 0.05 with adjustment
for an interim analysis. A two-sided, stratified logrank test
is applied with study site and first-line HDCT/ASCT (yes
or no) as variables for stratification. An unstratified log-
rank test and a multivariate proportional hazard Cox re-
gression model are calculated on an exploratory basis.
Secondary objectives are analyzed on a descriptive or ex-
ploratory basis. For hypothesis-generating tests explicit p
values are given without adjustment of the significance
level for multiple testing and therefore reflect Type 1 er-
rors related to the individual comparison and not the
overall experiment. OS is analyzed analogously to PFS.
Distribution of PFS and OS is estimated according to the
method of Kaplan-Meier. Known prognostic factors for
PFS and OS such as β2M and the number of prior treat-
ments are analyzed in a multivariate Cox model. For time
to best response cumulative incidence rates are calculated
with disease progression and death as competing risks.
Multivariate analyses including the comparison of time to
best response in both trial arms are performed using the
proportional hazards model for competing risks according
to Fine and Gray [56]. The sole purpose of this analysis is
the undistorted modeling of time to best response and not
the estimation of competing risks. PFS and OS according
to remission status before/after HDCT/ASCT are ana-
lyzed with landmark analyses (according to Anderson
[57]) and Cox regression model including remission status
(CR/VGPR: yes vs. no) as time-dependent co-variable.
Treatment response rates are evaluated with Fisher’s exact
test and Cochran/Armitage trend test. Demographic and
clinical characteristics at enrollment are analyzed for
homogeneity between both treatment groups. Toxicities
in both treatment groups are compared in terms of type,
frequency, CTC grading, and causality with Fisher’s exact
test and Cochran/Armitage trend test.
Interim analysis
An interim analysis of preliminary efficacy (PFS) and safety
(AEs) of the experimental trial arm (arm B) is performed
after 96 PFS relevant events. The results are presented to
the DSMB confidentially. The principal investigator only
gains insight if the DSMB recommends to close the trial
early or to alter the trial protocol. Additionally, the DSMB
receives an annual report of the number of (serious) AEs
and the number and severity of infections.
Discussion
For RMM patients no universal therapeutic standard ex-
ists. Novel agents, especially lenalidomide in combin-
ation with dexamethasone are well evaluated [8, 9] and
widely used in RMM patients. However, prospective data
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on salvage HDCT/ASCT are limited [49] and no pro-
spective, randomized trial evaluating the benefit of sal-
vage HDCT/ASCT versus continued novel agent-based
salvage treatment has been published. In the ReLApsE
trial, HDCT/ASCT is integrated into and compared
against the widely used Rd salvage regimen. Due to the
fact that patients randomized into the continued Rd arm
are recommended to receive salvage HDCT/ASCT for
their next relapse, comparison of early versus late sal-
vage HDCT/ASCT will be possible. Additionally, cyto-
genetic bone marrow analysis by iFISH is integrated into
the diagnostic workup at trial screening which will allow
for evaluation of the prognostic relevance of recurrent
cytogenetic aberrations in the context of salvage HDCT/
ASCT. The ReLApsE trial is therefore expected to
generate clinically relevant information to help guide
decision-making in the RMM setting.
Additional files
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